EO Care commends the Administration’s decision to move to reclassify cannabis from Schedule I to Schedule III. This decision is a watershed moment for adult Americans who currently or might benefit from the responsible use of cannabinoids, especially oncology patients and older adults. It’s a long overdue step that will reduce stigma, open doors for essential research and product development, and increase access to care for patients.
We also commend the Administration for their support of a safe and well-regulated hemp-derived cannabinoid industry. Such products already provide relief to millions and should be readily accessible to adults seeking to manage chronic pain, stress, sleep issues and cancer-related symptoms.
The rescheduling announcement and related hemp announcements will help cannabinoids find their rightful place in the practice of evidence-based medicine and eventually help enable reimbursement through employer benefit and payer plan coverage.
As the details of rescheduling and hemp policy continue to be finalized, EO is uniquely positioned to push cannabinoid-based research and care forward via the company’s personalized, clinically responsible cannabinoid guidance and data platform and via its clinically formulated cannabinoid products for pain, sleep, stress and appetite stimulation.
We look forward to continuing to serve patients and clinicians at leading hospitals and NCI-Designated Cancer Centers across the country. And we look forward to partnering closely with all relevant Federal agencies and playing a key role in the collection and analysis of detailed cannabinoid efficacy, safety and cost of care data.
About EO Care, Inc. EO is the leader in cannabinoid-based symptom management. The company provides personalized, clinically responsible care through its unique, scalable digital health platform and affordable, medicalized and federally legal hemp-derived cannabinoid products. Board members, advisors and investors include Regina Benjamin, MD, MBA, former Surgeon General of the United States; Kristi Savacool, former CEO of AON Hewitt; and Bill Van Faasen, former CEO of Blue Cross Blue Shield Massachusetts. For more information, visit eo.care.
As the leader in cannabinoid based symptom management for older adults, we applaud the Centers for Medicare & Medicaid Services (CMS) proposal to expand coverage for federally legal, hemp-derived cannabinoid-based products. At EO, we are uniquely positioned to meet the need of this new, covered cannabinoid care market.
At EO, we systematically track how patients feel and function after starting guided cannabis care. The data below come from real people using cannabis to manage symptoms such as pain, sleep disturbance, anxiety, and nausea/vomiting, under the guidance of our clinical protocols.
Meaningful improvements were reported by patients after one (1) week and sustained through four (4) weeks of guided cannabinoid care, particularly among people over 50 and cancer patients. Patients also reported low rates of use-limiting side effects with further reductions after receiving updated recommended product and/or dosing guidance via EO Care’s digital care platform.
Get special offers, event invites and the latest on new care offerings and product releases.
Wise Use for All
© 2025 All rights reserved. Patents pending. EO Care, Inc.
